Chronic Myelomonocytic Leukemia Recruiting Phase 1 Trials for Enasidenib (DB13874)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03515512IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationTreatment